Drug Discovery & DevelopmentOriginal article
Weekly Gilead and Merck oral HIV regimen maintains suppression in two phase 3 trials
Phase 3positiveislatravirlenacapavirPositive
AI Analysis
Summary
Gilead and Merck's investigational once-weekly oral HIV regimen combining islatravir and lenacapavir maintained virologic suppression at Week 48 in two Phase 3 trials enrolling 1,209 adults with suppressed HIV. The regimen reduced treatment burden from seven to one pill daily.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Patients
1,209
Outcome Details
Investigational once-weekly oral regimen maintained virologic suppression at Week 48 in two Phase 3 trials with 1,209 combined participants
Importance:7/10
Sentiment:
0.80
HIVPhase 3oral regimenvirologic suppressionpartnershiponce-weekly
Read the original article
Published by Drug Discovery & Development on July 21, 2026 4:43 PM